Tyra Biosciences, Inc. (TYRA) News
Follow Tyra Biosciences, Inc. (TYRA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 20 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Tyra Announces $400M Pricing of Common Stock and Pre-Funded Warrants
Tyra priced an underwritten offering expected to raise approximately $400.0 million from sales of common stock and pre-funded warrants.Key Highlights:Original SEC Filing: Tyra Biosciences, Inc. [ TYRA ] - 8-K - Sep. 14,
EARNINGS | Sep 15, 2026, 10:13 AM UTC
H
Stock Market Today: S&P 500, Dow and Nasdaq Futures Face Pressure as Brent Nears $108 and FOMC Commences Two-Day Meet— MSTR, CRWD, BMM in Focus
U.S. stock futures declined Tuesday as the Dow Jones, S&P 500 and Nasdaq 100 indices fell following Monday’s lower close. The Federal Open Market Committee’s two-day meeting will commence, with all eyes on the FOMC’s pol
LIVE | Sep 15, 2026, 09:33 AM UTC
M
Tyra Biosciences prices $400 million underwritten stock offering
Tyra Biosciences priced a $400 million underwritten offering of common stock and pre-funded warrants.
EQUITY | Sep 14, 2026, 10:45 AM UTC
L
Wedbush maintains Tyra Biosciences price target at $53.00
The item reports that Wedbush maintained its price target for Tyra Biosciences at $53.00 per share, citing ratings actions reported by Benzinga via TradingView News.
EQUITY | Sep 10, 2026, 01:11 PM UTC
L
HC Wainwright cuts Tyra Biosciences price target to $30
HC Wainwright & Co. maintained its Buy rating on Tyra Biosciences while cutting its price target to $30.00 a share from $45.00.
EQUITY | Sep 10, 2026, 10:50 AM UTC
M
TYRA’s dabogratinib advances to phase III for intermediate-risk NMIBC
Dabogratinib, an oral therapy for intermediate-risk NMIBC, posted 64% CR and 100% ORR in single marker lesions in phase II. Company says robust efficacy and safety support phase III advancement.
CENTRAL_BANK | Sep 09, 2026, 06:44 PM UTC
M
Tyra’s dabogratinib advances to phase III for MIBC
Dabogratinib, an oral FGFR3 inhibitor, reported phase II efficacy and safety in intermediate-risk MIBC, with 79% response and 64% CR rates at 60 mg. Phase III trials and UTUC expansion are planned.
EQUITY | Sep 09, 2026, 06:04 PM UTC
M
TYRA advances oral dabogratinib 60 mg to Phase III in NMIBC
SURF302 interim results for intermediate-risk NMIBC show oral dabogratinib 60 mg with 79% ORR and 64% CR, described as well-tolerated for chronic dosing. The 60 mg dose is advancing to Phase III.
EQUITY | Sep 09, 2026, 02:57 PM UTC
M
Tyra Biosciences shares drop 22% after bladder cancer Phase 2 data
Tyra Biosciences stock fell 22% after Phase 2 trial data for dabogratinib in 44 adults with early-stage non-muscle invasive bladder cancer failed to inspire confidence.
EQUITY | Sep 09, 2026, 02:44 PM UTC
M
Tyra Biosciences shares drop after clinical trial adverse events reported
Tyra Biosciences shares fell 23% to $20.50 after the company said some patients in a mid-stage bladder-cancer treatment trial reported side effects including fatigue, diarrhea and dry eyes.
EQUITY | Sep 09, 2026, 02:36 PM UTC
M
Tyra advances oral dabogratinib 60 mg for intermediate-risk NMIBC to Phase III
SURF302 initial results for oral dabogratinib 60 mg in intermediate-risk NMIBC report 79% ORR and 64% CR, with favorable safety, especially in single marker lesion patients, advancing to Phase III.
CENTRAL_BANK | Sep 09, 2026, 01:46 PM UTC
M
Tyra’s dabogratinib advances toward pivotal oncology trials
Dabogratinib, a highly selective oral FGFR3 inhibitor, is advancing toward pivotal trials in IR NMIBC, LG UTUC and ACH, supported by strong Phase 2 efficacy and safety data.
EQUITY | Sep 09, 2026, 01:40 PM UTC
M
Tyra shares drop more than 20% after Phase 2 bladder cancer results
Tyra Biosciences (TYRA) fell more than 20% in premarket trading after initial SURF302 Phase 2 results for its lead candidate dabogratinib in FGFR3-altered low bladder cancer patients.
EQUITY | Sep 09, 2026, 11:52 AM UTC
M
Tyra oral dabogratinib posts 79% ORR and 64% CR in Phase 2
Tyra Biosciences said oral dabogratinib in Phase 2 LG IR NMIBC showed favorable safety and strong efficacy: 79% ORR and 64% CR at 60 mg QD, supporting Phase 3 advancement and higher-dose exploration.
EQUITY | Sep 09, 2026, 11:15 AM UTC
M
Tyra Biosciences reports positive Phase 2 SURF302 results
Tyra Biosciences said initial Phase 2 SURF302 results were favorable and selected 60 mg once-daily as the potential dose for its planned registrational adjuvant strategy.
REGULATION | Sep 09, 2026, 11:13 AM UTC
L
Tyra Biosciences reports initial Phase 2 SURF302 results with dabogratinib
Tyra Biosciences reported initial Phase 2 SURF302 results for LG IR NMIBC using dabogratinib.
EQUITY | Sep 09, 2026, 11:01 AM UTC
M
Tyra Biosciences shares jump on next week Phase 2 readout
Tyra Biosciences said initial clinical results from a key Phase 2 bladder cancer study will be announced next week. Shares were up more than 15% at the time of writing.
EQUITY | Sep 04, 2026, 06:26 PM UTC
L
HC Wainwright maintains Tyra Biosciences $45 price target
HC Wainwright & Co. maintained its price target of $45.00 per share on Tyra Biosciences.
EQUITY | Sep 04, 2026, 04:16 PM UTC
L
Tyra Biosciences to host conference call on SURF302 initial results
Tyra Biosciences will host a conference call on initial results for oral dabogratinib from the SURF302 Phase 2 study for IR NMIBC on September 9, 2026.
EQUITY | Sep 04, 2026, 12:00 PM UTC
L
TYRA TYRA - Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
TYRA TYRA - Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
EARNINGS | Aug 04, 2026, 08:05 PM UTC